News from RSP, CMC Biologics and the NIH – People on the move

By Natalie Morrison

- Last updated on GMT

Related tags: Pharmacology, Pharmaceutical industry, Clinical trial

News from RSP, CMC Biologics and the NIH – People on the move presents its weekly round-up of the latest career changes in the pharmaceutical industry, including news from RSP, CMC Biologics and the NIH.

ReSearch Pharmaceutical Services(RPS)​ has appointed Stephen Kasay​ as its new chief information officer.

He will take charge of the P1 – IV solutions firm’s IT strategy development, tech infrastructure and its software systems.

 Daniel Perlman, chairman And CEO, said: "His addition will allow RPS to continue our transformation through world-class enabling technologies and to accelerate our goal of providing innovative clinical development solutions to the biopharmaceutical industry that improve quality and speed while driving down costs.”

CMC Biologics ​has hired Patricio Massera ​as general manager for its Copenhagen, Denmark, facility.

Massera will take charge of the quality operations and supply chain management as well as general oversight for the site – which provides contract development and manufacturing services.

Gustavo Mahler, global chief operations officer, said of Massera’s appointment: "His breadth of expertise in biopharmaceutical manufacturing and process improvement will be instrumental as we continue to prepare the Copenhagen manufacturing operation for commercial regulatory approval."

Sygnature Discovery​ has drafted in Colin Smith​ as head of computational chemistry and informatics.

Previously the director and head of research technologies at Prosidion, Smith claims he is joining Sygnature at a time of increased demand for its integrated drug services.

“Our customers are now mainly undertaking discovery projects which combine medicinal chemistry, computational chemistry and in vitro biology/screening at Sygnature,”​ he said.

INC Research ​has promoted Susan Akers-Smith​ to the role of VP of early phase oncology development.

Previously the contract research organisation’s (CRO) executive director of oncology clinical development, Akers-Smith will drive growth plans in the early phase arena.

Nicholas Kenny executive VP and general manager of oncology and hematology said: “We always strive to combine operational efficiency with the latest advancements in medical and regulatory knowledge to conduct cancer trials of the highest quality. Susan epitomizes the leadership traits necessary for this role and we look forward to leveraging her experience to further support the growing early phase oncology research needs of our customers.”

The US National Institute of Health (NIH) ​has named Janine Clayton​ its new director for the Office of Research on Women's Health (ORWH) and associate director for research on women's health.

Previously the the ORWH deputy director, Clayton has been serving in her new role on an interim basis since Vivian Pinn​ retired last year.

She also currently chairs the organisation’s working group on women in biomedical careers.

"Dr. Clayton's demonstrated leadership over the past year, scientific acumen, and commitment to this important area of research made her my first choice for the position,”​ said NIH director Francis Collins. "I look forward to seeing ORWH's progress in promoting women's health and sex differences research at NIH advance even further under Janine's direction.”

Michael Fort​ has joined Interface Clinical Services​ as a non-executive director.

Alongside his new role with the firm – who provides clinical improvement programmes for the UK’s National Health Service (NHS) – Fort is also director at Globus Shetland.

Fort said he believes Interface has a big opportunity to grow in a fragmented but very large marketplace.

Related topics: Markets & Regulations

Related news

Show more

Follow us


View more